Source: Eur Respir J, 55 (2) 1902223; 10.1183/13993003.02223-2019
Disease area: -



Rating:

Share or cite this content

Citations should be made in the following way:
Stefan Pabst, Christian Grohé, Dirk Skowasch. Prevalence of sarcoidosis-associated pulmonary hypertension: cumulative analysis of two PULSAR studies. Eur Respir J, 55 (2) 1902223; 10.1183/13993003.02223-2019

Member's Comments

No comment yet.

Related content which might interest you: Patterns of pulmonary hypertension in Egyptian patients with COPD: A retrospective analysis Source: Virtual Congress 2021 – Pulmonary hypertension in the COVID-19 pandemic and beyond Year: 2021 Analysis of mortality risk factors in a population with pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension Source: Annual Congress 2010 - Pulmonary hypertension Year: 2010 Risk stratification in pulmonary arterial hypertension using Bayesian analysis Source: Eur Respir J, 56 (2) 2000008; 10.1183/13993003.00008-2020 Year: 2020 Comprehensive analysis of inflammatory markers in chronic thromboembolic pulmonary hypertension patients Source: Eur Respir J 2014; 44: 951-962 Year: 2014 An epidemiological study of pulmonary arterial hypertension Source: Eur Respir J 2007; 30: 104-109 Year: 2007 Pulmonary hypertension in COPD: Prevalence and characteristics Source: Annual Congress 2012 - COPD comorbidities II Year: 2012 The association of diuretics treatment with hospitalization rates of patients with chronic obstructive pulmonary disease and pulmonary hypertension: a population-based study Source: Virtual Congress 2020 – Pulmonary hypertension in lung diseases Year: 2020 Genetic analyses in a cohort of children with pulmonary hypertension Source: Eur Respir J 2016; 48: 1118-1126 Year: 2016 Riociguat for the treatment of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: Real-life data from the EXPERT registry Source: International Congress 2015 – Pulmonary hypertension: new treatment insights Year: 2015 Prevalence of pulmonary hypertension among COPD patients: screening by echocardiography and NT-PROBNP Source: Annual Congress 2009 - Pulmonary vascular diseases Year: 2009 Physiological predictors of survival in patients with sarcoidosis-associated pulmonary hypertension: results from an international registry Source: Eur Respir J, 55 (5) 1901747; 10.1183/13993003.01747-2019 Year: 2020 Mortality in pulmonary arterial hypertension: prediction by the 2015 European pulmonary hypertension guidelines risk stratification model Source: Eur Respir J, 50 (2) 1700740; 10.1183/13993003.00740-2017 Year: 2017 Prevalence of pulmonary arterial hypertension in idiopathic pulmonary fibrosis: a multicenter study Source: Eur Respir J 2007; 30: Suppl. 51, 119s Year: 2007 Prevalence of pulmonary hypertension in pulmonary sarcoidosis: the first large European prospective study Source: Eur Respir J, 54 (4) 1900897; 10.1183/13993003.00897-2019 Year: 2019 Long-term safety and clinical effects of riociguat in chronic thromboembolic pulmonary hypertension and pulmonary arterial hypertension: Interim analysis of a phase II extension study Source: Annual Congress 2010 - Pulmonary hypertension updates Year: 2010 Chronic thromboembolic pulmonary hypertension in acute pulmonary embolism: A risk factor evaluation study Source: Virtual Congress 2020 – Pulmonary embolism Year: 2020 Risk assessment in scleroderma patients with newly diagnosed pulmonary arterial hypertension: application of the ESC/ERS risk prediction model Source: Eur Respir J, 52 (4) 1800497; 10.1183/13993003.00497-2018 Year: 2018 Real world data from hospital episode statistics can be used to determine patients at risk of idiopathic pulmonary arterial hypertension Source: International Congress 2018 – Clinical aspects of pulmonary hypertension Year: 2018 Risk assessment in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension Source: Eur Respir J, 53 (6) 1802004; 10.1183/13993003.02004-2018 Year: 2019 Effect of selexipag on long-term outcomes in key subgroups of patients with pulmonary arterial hypertension (PAH): GRIPHON study results Source: International Congress 2015 – Pulmonary hypertension: new treatment insights Year: 2015